
Pharmacy & health retail
Aspen JSE: APN
- Last price
- R158.26
- Today
- -0.28%
Price and technicalsThe chart.
Aspen
Loading prices…
Aspen EdgeLong or short?
Long bias.
7 point long2 point short2 neutral
What it means
Most of the evidence supports Aspen’s price: the trend, the numbers or both point up. On these checks alone, the case leans long.
The price is above its 50-day and 200-day averages: the trend is up. The chart and the overall tally agree.
Technical
Long-term trend
Points long
+13.3% against the 200-day average
Trading above its 200-day average: the long-term trend is up.
Why it matters. The 200-day average is the most watched line in the market. Shares above it tend to attract buyers; below it, sellers.
50-day against 200-day
Points long
50-day +10.6% against the 200-day
The 50-day average is above the 200-day: the medium-term trend is up.
Why it matters. When the shorter average crosses above the longer one, momentum is building; below, it is fading.
Against the Top 40
Points long
+4.0% in three months, Top 40 -0.9%
Beat the Top 40 by 4.9 points over three months.
Why it matters. Shares that are beating the market tend to keep doing so for a while (momentum); laggards tend to keep lagging.
RSI (14-day)
Neutral
RSI 50
Neither stretched nor oversold.
Why it matters. The relative strength index measures how fast the price has moved. Extremes tend to cool off.
Technical gauge
Points long
4 up, 2 neutral, 3 down
Nine signals (moving averages, momentum, MACD and stochastic) read up.
Why it matters. A broad reading of the usual technical signals, so no single indicator decides.
Fundamental
Revenue growth
Points short
-16.9% on the year
Sales are shrinking.
Why it matters. Over time share prices follow sales and profits. Growth above inflation means real growth.
Valuation against peers
Points long
11.7x forward earnings, Pharmacy & health retail 14.7x
Cheaper than the Pharmacy & health retail median on next year’s earnings.
Why it matters. A lower price for each rand of expected profit leaves more room for the price to rise, and less to fall.
Dividend yield
Points short
1.5%, Pharmacy & health retail 2.8%
Pays less than its peers for each rand invested.
Why it matters. A higher yield is income while you wait, and often a sign the price is low against the business.
Balance sheet
Points long
Debt 19% of equity, store leases included
Little debt against what shareholders own.
Why it matters. Heavy debt makes profits swing harder when rates or sales move, both ways. Retailers carry store leases as debt, so we only flag it at twice equity.
Analyst targets
Neutral
Average target +9.9% from here (3 analysts)
The price is close to the average target.
Why it matters. Sell-side analysts model the business in detail. Their targets are opinions, but they move money.
Backdrop
The economy
Points long
Retail sales
Helping: retail sales picking up.
Why it matters. What we think moves Pharmacy & health retail, read against the latest official numbers.
Each check points long (supports the price), short (weighs on it) or neutral; the lean is the count. Prices and company numbers via Yahoo Finance, the economy from official releases. A reading of the evidence, not a forecast. Artive Capital doesn’t raise outside capital; it only trades and invests Artive’s own, and has no clients. This is a screen we use to decide where to look, not a recommendation to buy or sell anything.
Company overviewIn plain words.
- 01What it sells
- Medicines, with consumer brands sold in pharmacies and shops as well as hospital and prescription products, in Africa and abroad.
- 02How it makes money
- Branded and generic medicines, and making medicines for other companies.
- 03What moves the share
- Pricing, exchange rates and its manufacturing contracts.
- Industry
- Drug Manufacturers - Specialty & Generic
- Head office
- Durban
- Financial year ends
- June
- Last results
- 02 Sept 2026
- Last ex-dividend date
- 07 Oct 2026
- Website
- aspenpharma.com ↗
Who runs it
- Stephen Bradley Saad BCom, CA(SA)Group CEO & Executive Director
- Sean M. CapazorioGroup CFO & Executive Director
- Lorraine HillGroup Chief Operations Officer
- Michael Guy Attridge B.Com., CA(SA)Group Chief Advisor
- Raeesa KhanGroup Company Secretary & Chief of Staff
- Samer KassemChief Executive Officer of Aspen Global Incorporated
As listed by Yahoo Finance, which can lag changes the company has announced. The company’s own website has the current line-up.
The companyWhat it owns, and who owns it.
Brands and businesses
–
The main ones, from the company’s website and annual report. Check the latest annual report: groups buy and sell businesses.
Ownership
- Insiders
- 20.4%
- Directors, founders and some strategic holders, as Yahoo classes them
- Institutions
- 64.4%
- 149 institutions hold shares
- Other holders and the public
- 15.2%
Ownership breakdown from Yahoo Finance.
FinancialsThe numbers, at a glance.
- Market value
- R68.0bn
- Price to earnings
- –Forward 11.7x
- Dividend yield
- 1.5%
- Revenue
- R34.9bnlast 12 months
- Revenue growth
- -16.9%
- Earnings growth
- –
- Operating margin
- -5.9%
- Net margin
- 7.6%
- Return on equity
- -1.1%
- Debt to equity
- 19%
- Cash
- R16.0bnDebt R15.6bn
- Free cash flow
- R2.7bn
- R38.6bn2022
- R40.7bn2023
- R44.7bn2024
- R43.4bn2025
- R6.5bn2022
- R5.2bn2023
- R4.4bn2024
- -R1.1bn2025
Headline numbers from Yahoo Finance, in rand, from the latest reported results. Growth compares with the same period a year earlier. Treat them as a sneak peek: read the company’s own results on SENS before relying on any of them.
What analysts sayThe sell-side view.
Consensus
Buy
3 analysts · average 2.0 on a 1 (strong buy) to 5 (strong sell) scale
111- Strong buy 1
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Average 12-month target
R172.67
+9.1% vs today’s price
Target range
Low R165.00High R183.00
How the view has moved
- 2 months ago
- 1 month ago
- Now
Third-party ratings and price targets from sell-side analysts, as aggregated by Yahoo Finance. Yahoo does not name the analysts or firms behind JSE ratings, so we can’t either. This is what others say, not our view, and not advice.
In the newsMarkets, and everything else.
No headlines about this company in the last 30 days.
Headlines from Moneyweb, BusinessTech, TechCentral, Daily Maverick, Bizcommunity, News24, IOL, The Citizen, SABC News, The South African, Food For Mzansi and Marketaux. Matched to companies and sorted into topics automatically, so the odd one may be off. Not advice.
Also inPharmacy & health retail
All the shares we follow →Artive Capital doesn’t raise outside capital; it only trades and invests Artive’s own, and has no clients. Nothing on this page is advice or a recommendation to buy or sell.
The Monday briefCommerce, in your inbox.
Every Monday: last week’s moves in JSE commerce, your own shares, and the results and numbers due this week. Free, and you can unsubscribe any time.
We only use your email to send the brief. Privacy policy.
We don’t take outside money, but we always like talking markets and commerce.
For media, research and partnership questions, send us an email.
